問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Internal Medicine

更新時間：2023-09-19

馮博皓Feng, Po-Hao
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

80Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

馮博皓

List

120Cases

2022-11-15 - 2034-07-12

Others

xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    AlectinibEntrectinibEntrectinibPralsetinibDurvalumab

Participate Sites
8Sites

Recruiting8Sites

2023-07-01 - 2030-06-30

Phase II/III

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%

  • Condition/Disease

    Advanced Non-Small Cell Lung Cancer

  • Test Drug

    REGN3767 (Fianlimab) REGN2810 (Cemiplimab)

Participate Sites
8Sites

Recruiting8Sites

2024-02-06 - 2029-08-30

Phase II

Active
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC

  • Condition/Disease

    NSCLC

  • Test Drug

    REGN3767 (Fianlimab) REGN2810 (Cemiplimab)

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2024-10-01 - 2034-06-01

Phase III

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous(NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression of 1% to 49%.

  • Condition/Disease

    Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression of 1% to 49%

  • Test Drug

    Relatlimab & Nivolumab Fixed Dose Vial (BMS-986213)

Participate Sites
2Sites

Recruiting2Sites

2017-04-01 - 2020-06-01

Phase III

Open-label extension study to evaluate the long-term safety and tolerability of dupilumab inpatients with asthma who participated in a previous dupilumab asthma clinical study

  • Condition/Disease

    asthma

  • Test Drug

    Dupilumab

Participate Sites
4Sites

Terminated3Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

鍾啟禮
Taipei Medical University Hospital

Division of Thoracic Medicine

2019-06-01 - 2022-12-31

Phase II

A PHASE 2, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, CONTROLLED STUDY OF PEMETREXED MAINTENANCE WITH OR WITHOUT ADXS11-001 IMMUNOTHERAPY IN SUBJECTS WITH HUMAN PAPILLOMAVIRUS-POSITIVE, NON-SQUAMOUS, NONSMALL CELL LUNG CARCINOMA FOLLOWING FIRST-LINE INDUCTION CHEMOTHERAPY

  • Condition/Disease

    LUNG CARCINOMA

  • Test Drug

    ADXS11-001

Participate Sites
9Sites

Terminated9Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2010-09-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2016-10-21 - 2018-11-19

Phase II

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered ALS-008176 Regimens in Adult Subjects Hospitalized with Respiratory Syncytial Virus

  • Condition/Disease

    Respiratory Syncytial Virus (RSV)

  • Test Drug

    ALS-008176 (JNJ-64041575)

Participate Sites
6Sites

Terminated6Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2015-07-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2017-08-24 - 2019-09-30

Phase III

A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)

  • Condition/Disease

    Small-Cell Lung Cancer (SCLC)

  • Test Drug

    Durvalumab; Tremelimumab

Participate Sites
11Sites

Terminated10Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

夏德椿
China Medical University Hospital-Taipei

未分科

1 7 8 9 10 11 12
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB